Recovery of neurogenic amines in phenylketonuria mice after liver-targeted gene therapy

被引:9
|
作者
Yagi, Hiroya [1 ,2 ]
Sanechika, Sho [3 ]
Ichinose, Hiroshi [3 ]
Sumi-Ichinose, Chiho [4 ]
Mizukami, Hiroaki [1 ]
Urabe, Masashi [1 ]
Ozawa, Keiya [1 ]
Kume, Akihiro [1 ]
机构
[1] Jichi Med Univ, Div Genet Therapeut, Shimotsuke, Tochigi 3290498, Japan
[2] Univ Tsukuba, Inst Clin Med, Dept Obstet & Gynecol, Tsukuba, Ibaraki 305, Japan
[3] Tokyo Inst Technol, Dept Life Sci, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 227, Japan
[4] Fujita Hlth Univ, Sch Med, Dept Pharmacol, Toyoake, Aichi 47011, Japan
关键词
MOUSE MODEL; HYDROXYLASE ACTIVITY; PHENYLALANINE; BRAIN; SEROTONIN; TETRAHYDROBIOPTERIN; TRANSPORT; PKU;
D O I
10.1097/WNR.0b013e32834e3a87
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Phenylketonuria (PKU) is a common genetic disorder arising from a deficiency of phenylalanine hydroxylase. If left untreated, the accumulation of phenylalanine leads to brain damage and neuropsychological dysfunction. One of the abnormalities found in hyperphenylalaninemic patients and a mouse model of PKU is an aminergic deficit in the brain. We previously showed correction of hyperphenylalaninemia and concomitant behavioral recovery in PKU mice after liver-targeted gene transfer with a viral vector. Here, we addressed whether such a functional recovery was substantiated by an improved amine metabolism in the brain. After gene transfer, brain dopamine, norepinephrine, and serotonin levels in the PKU mice were significantly elevated to normal or near-normal levels, along with systemic improvement of phenylalanine catabolism. The results of biochemical analyses validated the efficacy of PKU gene therapy in the central nervous system. NeuroReport 23:30-34 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 50 条
  • [41] A Non-Invasive Bedside Breath Test (BreathID®) for Real Time Monitoring of Liver-Targeted Gene Therapy in Methylmalonic and Propionic Acidemias
    McCoy, Samantha
    Pass, Alexandra
    Shchelochkov, Oleg
    Sloan, Jennifer
    Ferry, Susan
    Van Ryzin, Carol
    Manoli, Irini
    Venditti, Charles
    MOLECULAR THERAPY, 2021, 29 (04) : 255 - 255
  • [42] Liver-targeted prodrugs of 2′-C-methyladenosine for therapy of hepatitis C virus infection
    Hecker, Scott J.
    Reddy, K. Raja
    van Poelje, Paul D.
    Sun, Zhili
    Huang, Wenjian
    Varkhedkar, Vaibhav
    Reddy, M. Venkat
    Fujitaki, James M.
    Olsen, David B.
    Koeplinger, Kenneth A.
    Boyer, Serge H.
    Linemeyer, David L.
    MacCoss, Malcolm
    Erion, Mark D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (16) : 3891 - 3896
  • [43] MEDI 271-HepDirect® prodrugs of 2'-methyladenosine for liver-targeted therapy of hepatitis C
    Hecker, Scott J.
    Reddy, K. Raja
    van Poelje, Paul D.
    Sun, Zhili
    Mali, V. Reddy
    Huang, Wenjian
    Varkhedkar, Vaibhav
    Fujitaki, James
    Insko, Michael
    Krutil, Douglas
    Chi, Bert
    Olsen, David B.
    Koeplinger, Kenneth A.
    Boyer, Serge H.
    Linemeyer, David
    MacCoss, Malcolm
    Erion, Mark D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [44] Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
    Han, Sang-oh
    Ronzitti, Giuseppe
    Arnson, Benjamin
    Leborgne, Christian
    Li, Songtao
    Mingozzi, Federico
    Koeberl, Dwight
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2017, 4 : 126 - 136
  • [45] Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism
    Zhao, Yuying
    Tan, Hanxu
    Zhang, Juping
    Zhan, Dandan
    Yang, Bowen
    Hong, Shicui
    Pan, Bo
    Wang, Neng
    Chen, Tongkai
    Shi, Yafei
    Wang, Zhiyu
    JOURNAL OF NANOBIOTECHNOLOGY, 2024, 22 (01)
  • [46] Phenotypic Reversion of Fair Hair upon Gene Therapy of the Phenylketonuria Mice
    Thoeny, Beat
    Ding, Zhaobing
    Rebuffat, Alexandre
    Viecelli, Hiu Man
    HUMAN GENE THERAPY, 2014, 25 (07) : 573 - 574
  • [47] Therapeutic Thresholds for Liver-Directed Gene Therapy of Phenylketonuria (PKU)
    Hamman, Kelly
    Harding, Cary O.
    MOLECULAR THERAPY, 2009, 17 : S68 - S68
  • [48] Effective Prevention of Liver Fibrosis by Liver-targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in a Rat Liver Fibrosis Model
    Abe, Hiroyuki
    Kamimura, Kenya
    Kobayashi, Yuji
    Ohtsuka, Masato
    Miura, Hiromi
    Ohashi, Riuko
    Yokoo, Takeshi
    Kanefuji, Tsutomu
    Suda, Takeshi
    Tsuchida, Masanori
    Aoyagi, Yutaka
    Zhang, Guisheng
    Liu, Dexi
    Terai, Shuji
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2016, 5 : e276
  • [49] Effective Prevention of Liver Fibrosis by Liver-Targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in Rat Liver Fibrosis Model
    Abe, Hiroyuki
    Kamimura, Kenya
    Kobayashi, Yuji
    Ohtsuka, Masato
    Miura, Hiromi
    Ohashi, Riuko
    Yokoo, Takeshi
    Kanefuji, Tsutomu
    Suda, Takeshi
    Tsuchida, Masanori
    Aoyagi, Yutaka
    Zhang, Guisheng
    Liu, Dexi
    Terai, Shuji
    MOLECULAR THERAPY, 2015, 23 : S234 - S234
  • [50] Clearance of Intracellular Free Cholesterol by Liver-Targeted LNP-mRNA Therapy Reverses NASH Pathology
    Strough, Garrett
    Warren, Iyan
    Sahbani, Karim
    Plencner, Stephen
    Laih, Ian
    de Oliveira, Guilherme Cherman Perdigao
    Topors, Mourad
    MOLECULAR THERAPY, 2023, 31 (04) : 587 - 587